Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Long-Term Debt Repayments (2018 - 2020)

Anaptysbio (ANAB) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $1.4 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Long-Term Debt Repayments fell 26.67% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2020, down 81.67%, and an annual FY2020 reading of $1.4 million, down 81.67% over the prior year.
  • Long-Term Debt Repayments was $1.4 million for Q1 2020 at Anaptysbio, down from $1.9 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.9 million in Q2 2018 and bottomed at $1.2 million in Q1 2018.
  • Average Long-Term Debt Repayments over 3 years is $1.8 million, with a median of $1.9 million recorded in 2018.
  • The sharpest move saw Long-Term Debt Repayments surged 50.0% in 2019, then fell 26.67% in 2020.
  • Year by year, Long-Term Debt Repayments stood at $1.9 million in 2018, then changed by 0.0% to $1.9 million in 2019, then decreased by 26.67% to $1.4 million in 2020.
  • Business Quant data shows Long-Term Debt Repayments for ANAB at $1.4 million in Q1 2020, $1.9 million in Q4 2019, and $1.9 million in Q3 2019.